Skip to main content

Table 1 Baseline demographic and clinical characteristics—comparison between the two study groups (2866 participants)

From: HbA1C variability among type 2 diabetic patients: a retrospective cohort study

Variable HbA1C variability (N = 632) No HbA1C variability (N = 2234) p value
Gender
 Male: (N = 1242) 43.4% (274) 43.3% (968) 0.991
 Female: (N = 1624) 56.6% (358) 56.7% (1266)  
Country of origin
 Israel: (N = 910) 44.7% (281) 28.2% (629) < 0.001
 USA and Western Europe: (N = 26) 0.3% (2) 1.1% (24)  
 Russia and Eastern Europe: (N = 585) 16.4% (103) 21.6% (482)  
 Asia and Africa: (N = 1285) 37.4% (235) 47.1% (1050)  
 South America: (N = 49) 1.1% (7) 1.9% (42)  
Age (beginning of study) 55.6 ± 7.8 59.5 ± 7.2 < 0.001
Smokers: (N = 895) 37.1% (228) 31.3% (667) 0.007
Ischemic heart disease diagnosis: (N = 903) 36.2% (222) 32.0% (681) 0.052
Obesity BMI ≥ 30: (N = 1274) 49.0% (308) 43.7% (966) 0.018
Hyperlipidemia diagnosis in medical records (N = 2235) 78.3% (495) 77.9% (1740) 0.816
Hypertension diagnosis in medical records (N = 1827) 61.6% (386) 64.5% (1441) 0.114
Visits at Diabetic clinic: (N = 693) 28.6% (181) 22.9% (512) 0.003
HbA1C counts during study period 20.5 ± 6.8 21.09 ± 6.8 0.057